The androgen receptor (AR) regulates muscle anabolism and bone density, but the classic androgen ligands – testosterone and anabolic-androgenic steroids – stimulate it without tissue discrimination. Muscle stimulation is then accompanied by stimulation of the prostate, skin and gonadal axis, which drives the adverse effect profile of this entire class. Selective androgen receptor modulators (SARMs) are pharmacology’s answer to this problem: molecules that were supposed to preserve the anabolic stimulation of AR in muscle and bone, while limiting activity in androgen-dependent tissues such as the prostate.
MK-2866 belongs to the Pro-Body catalog line SARMs — research reagents from the group of selective androgen receptor modulators. MK-2866 (ostarine, enobosarm, code GTx-024) is a representative of this class with the most extensive clinical documentation of all SARMs. Pro-Body supplies it in line Endogenic as a research reagent in format 10 mg × 60 capsules.
Chemically, it is a small non-steroidal molecule from the arylpropionamide group – not a steroid, despite a similar molecular attachment point. In terms of mechanism, it is a tissue-selective androgen receptor ligand: in preclinical models it behaves as a full AR agonist in muscle and bone, with minimal androgenic activity in the prostate. MK-2866 was developed by the American biopharmaceutical company GTx, and the characterization of this molecule includes a phase I–III clinical trial program for sarcopenia (age-related loss of muscle mass) and cachexia (cancer cachexia).
This makes ostarine the most clinically tested SARM – no other compound of this class has undergone such an extensive research program in humans. In research terms, ostarine remains a model tool for studying the tissue selectivity of AR ligands, muscle anabolism and bone metabolism. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
REGULATORY STATUS
MK-2866 is not registered as a drug in the EU or USA. The GTx clinical program (phase I-III) did not achieve a primary endpoint that fully satisfied the registration authorities, so ostarine was not authorized by the FDA or EMA. The FDA also issued Warning Letters against entities marketing SARMs as ingredients of human products. MK-2866 has been on the WADA Prohibited List in category S1.2 (other anabolic agents) continuously since 2008. Communicating the product as a “SARM for mass”, a “safer steroid” or an “anabolic without side effects” is contrary to the Research Use Only framework.